NCT00327379终止3 期
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- Bayer
- 入组人数
- 54
- 主要终点
- Percent of patients requiring a blood transfusion (blood or packed red blood cells, autologous or allogenic)
研究概览
简要总结
The objective of this study is to evaluate the safety and efficacy of aprotinin as compared to placebo, in reducing the need for blood transfusion in adult subjects undergoing elective spinal fusion surgery involving 3 to 7 vertebral levels with instrumentation
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects requiring elective spinal fusion surgery involving 3 to 7 vertebral levels with instrumentation. One vertebral level is defined as encompassing two vertebral bodies and one inter-vertebral disc space, so that a contiguous spinal fusion involving 3 vertebral levels would include 4 vertebral bodies and 3 inter-vertebral disc spaces.
排除标准
- •Subjects with previous exposure to aprotinin in the last 6 months. If the subject has undergone cardiac surgery in the last 6 months, all attempts should be made to ascertain if aprotinin was administered during cardiac surgery. If no records are available, or if the subject received aprotinin, the subject should be excluded.- Subjects with a known or suspected allergy to aprotinin.
- •Subjects with sepsis or a known bone infection.- Subjects with known bone malignancy.
- •Subjects with a creatinine clearance less than 30mL/min as calculated by the Cockcroft-Gault formula.
- •Subjects with a history of bleeding diathesis or known coagulation factor deficiency.
- •Subjects with failure of a major organ system or any active significant medical illness that in the opinion of the Investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study
- •Subjects who refuse to receive allogenic blood products for religious or other reasons.
- •Subjects whose preoperative red blood cell volume is so low that a blood transfusion would be likely to be given perioperatively (preoperative hematocrit or hemoglobin values <24% or <8 g/dl, respectively).
- •Subjects who have participated in an investigational drug study within the past 30 days
- •Subjects with a history of deep vein thrombosis or pulmonary embolism.
- •Subjects who are pregnant or breast feeding.
- •Women of childbearing potential in whom the possibility of pregnancy cannot be excluded by a negative serum pregnancy test at screening.
- •Women of childbearing potential who are not using a reliable method of contraception.
- •Planned use of other antifibrinolytic agents.
- •Subjects on chronic anticoagulant treatment with Vit K antagonists that cannot be temporarily discontinued for the surgical procedure (as per local practices).
研究组 & 干预措施
Arm 1
Experimental
干预措施: Trasylol (Aprotinin, BAYA0128) (Drug)
Arm 2
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Percent of patients requiring a blood transfusion (blood or packed red blood cells, autologous or allogenic)
时间窗: anytime in the intra-operative or postoperative period (up to the earlier of Day 7 or discharge).
次要结局
- The percent of patients receiving an allogenic transfusion of blood or packed red cells during surgery and up to the earlier of Day 7 or discharge(surgery to discharge)
- The percent of patients who did and did not predonate blood receiving an allogenic transfusion of blood or packed red cells during surgery and up to the earlier of Day 7 or discharge(surgery to discharge)
- The number of units of blood or packed red cells transfused. There will be analyses for the combination of autologous and allogenic transfusion and for allogenic alone(surgery to discharge)
- The number of units of blood or packed red cells transfused per patient requiring transfusion(surgery to discharge)
- Drainage (in milliliters) from the operative site in the first 8 hours postoperatively, and total drainage until removal of drains or until hospital discharge (whichever is earlier)(surgery to discharge)
- Blood loss during surgery, based on qualitative and quantitative estimates(surgery)
- The change from preoperative hemoglobin concentration to postoperative hemoglobin concentration (obtained in the morning of Day 3, or, if transfused earlier, prior to transfusion).(pre-op and day 3 post surgery)
- Surgeons assessment of the degree to which bleeding obscured his/her view of the surgical field, relative to past, similar procedures(surgery to discharge)
- The percent of patients receiving colloid or other blood products, and the number of units transfused(surgery to discharge)
- Changes in blood markers related to inflammation and blood coagulation(surgery to discharge)
- Changes in FEV1(surgery to discharge)
研究者
相似试验
终止
3 期
Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total CystectomyBlood Loss, SurgicalPostoperative HemorrhageNCT00306150Bayer57
已完成
3 期
Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip ReplacementBlood Loss, SurgicalNCT00668031Bayer359
终止
3 期
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and PleasureDepressive Disorder, MajorAnhedoniaNCT06635135Janssen Research & Development, LLC47
终止
3 期
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With AticaprantDepressive Disorder, MajorAnhedoniaNCT06514742Janssen Research & Development, LLC101
已完成
3 期
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant TherapyDepressive Disorder, MajorAnhedoniaNCT05455684Janssen Research & Development, LLC513